Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Intradermal Influenza Vaccine (2009-2010)
NCT00945438Phase 2
Key facts
- Status
- Completed
- Start
- May 2009
- Primary completion
- Jun 2009
- Countries
- 1
- Sponsor
- Sanofi
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Drugs
- IDflu
- Conditions
- influenza
01
Overview
Phase 2, open-label trial of IDflu in influenza (2 arms), sponsored by Sanofi. Primary endpoints: Immunogenicity of Intradermal Influenza vaccine and Safety of Intradermal Influenza vaccine. Started May 2009; status: completed.
02
Design
2 arms- Study design
- Non-randomizedOpen-label
Group 1 (18-59 years)
Participants aged 18 to 59 years receiving 0.1 mL Intradermal vaccine.
Group 2 (60+ years)
Participants aged 60 years or older receiving 0.5 mL Intradermal vaccine.
03
Who it enrols
Adults 18 years and older, including elderly, without acute illness, immunodeficiency, bleeding disorders, or recent vaccination.
04
Endpoints
Primary
Immunogenicity of Intradermal Influenza vaccine
Safety of Intradermal Influenza vaccine
Beyond the preview
Go deeper on NCT00945438.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00945438.